Future Outlook of the Cytokine Release Syndrome Treatment Market: Growth, Trends, and Emerging Opportunities Explored
Get 15% OFF on all 2025 Global Market Reports until March 31st! Apply code FY25SAVE and grab your savings today!
How has the cytokine release syndrome treatment market size evolved in recent years?
The market size for cytokine release syndrome treatments has experienced significant expansion in the past few years. It is expected to surge from $1.25 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 13.7%. The historical growth can be credited to factors such as increased incidence of cancer, the growing popularity of immunotherapy, the escalation in biopharmaceutical investments, an upsurge in clinical trials, and the expansion of personalized medicine.
What are the predictions for the cytokine release syndrome treatment market size in the coming years?
The market for cytokine release syndrome treatment is predicted to experience substantial growth in the upcoming years, expanding to $2.35 billion by 2029 with a compound annual growth rate (CAGR) of 13.4%. Factors contributing to this projected growth during the forecast period include an escalating prevalence of autoimmune disorders, a rise in cancer therapies, the increased availability of targeted treatments, elevated investments in biotechnology and life sciences, and a higher usage of monoclonal antibodies. Key trends anticipated during the forecast period consist of the integration of biomarker-based therapies, creation of next-generation IL-6 inhibitors, progress in CAR-T cell therapy, increased usage of biosimilars, and advancements in monoclonal antibody therapies.
Get your cytokine release syndrome treatment market report here!
What key factors are fueling the growth of the cytokine release syndrome treatment market?
The growth of the cytokine release syndrome (CRS) treatment market is anticipated to surge due to the rising prevalence of cancer treatments. The ascending trend in cancer treatment prevalence can be attributed to the increasing global cancer rates and advancements in diagnostic technologies, which allow for more sophisticated early detection and a wider array of treatment options. Additionally, longer survival rates and better access to healthcare are increasing the demand for such treatments. CRS treatment comprises supportive care, anti-cytokine therapies, and continuous monitoring to control symptoms and lower the inflammatory response triggered by cancer treatments. For example, the National Health Service (NHS), a healthcare system based in the UK, reported in January 2023 that over 320,000 individuals were provided with cancer treatments from November 2021 to October 2022; this is the largest number ever documented and an increment of over 8,000 from the previous record. As such, the cytokine release syndrome treatment market is being fueled by the escalating prevalence of cancer treatments.
How is the global cytokine release syndrome treatment market divided into key segments?
The cytokine release syndrome treatment market covered in this report is segmented –
1) By Drug Type: Corticosteroids, Monoclonal Antibodies, Other Immunosuppressants
2) By Administration: Intravenous, Subcutaneous, Oral
3) By Application: Oncological Treatments, Autoimmune Disorders, Other Applications
4) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone
2) Monoclonal Antibodies: Tocilizumab (IL-6 Inhibitor), Siltuximab (IL-6 Inhibitor), Anakinra (IL-1 Receptor Antagonist)
3) Other Immunosuppressants: Janus Kinase (JAK) Inhibitors, Calcineurin Inhibitors, Tumor Necrosis Factor (TNF) Inhibitors
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20542&type=smp
Who are the key firms paving the way for growth in the cytokine release syndrome treatment market?
Major companies operating in the cytokine release syndrome treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Incyte Corporation, Swedish Orphan Biovitrum AB (publ), Bio-Techne Corporation, GenScript Biotech Corporation, Abcam plc, Applied Biological Materials Inc., Poolbeg Pharma, arigo Biolaboratories Corp., CytoAgents Inc, bluebird bio Inc.
Which trends are expected to transform the cytokine release syndrome treatment market?
Leading businesses in the cytokine release syndrome treatment market are perfecting drug delivery technologies such as intravenous infusion, with goals to enhance treatment accuracy, minimize side effects and improve patient results. The use of intravenous infusion in treating cytokine release syndrome guarantees swift and precise drug introduction into the bloodstream, prompting immediate therapeutic response. In a notable development from September 2023, Chugai Pharmaceutical Co. Ltd., a firm rooted in Japan, gained regulatory permission for Actemra (tocilizumab), a humanized anti-IL-6 receptor monoclonal antibody from the Ministry of Health, Labor, and Welfare, a governing authority in Japan. The approval was given to treat cytokine release syndrome (CRS) triggered by a range of cancer treatments. Actemra Intravenous Infusion, available in doses of 80 mg, 200 mg, and 400 mg, offers an additional means of treating cytokine release syndrome instigated by cancer therapies. This new application allows Actemra to be employed as an anti-cytokine therapy for CRS caused by cancer treatments, beyond the realm of tumor-specific T-cell infusion therapy.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20542
What regions are contributing significantly to the growth of the cytokine release syndrome treatment market?
North America was the largest region in the cytokine release syndrome treatment market in 2024. The regions covered in the cytokine release syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Drugs for Immunotherapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report
Cellular Immunotherapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report
Cancer Immunotherapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
